The Department of Health and Social Care (DHSC) has finally published its response to the 2022 consultation on hub and spoke dispensing.
Considering the consultation evidence and further discussions, the government has expressed its intention to progress the proposals for enabling hub and spoke models
across different legal entities as soon as possible.
This will be achieved by using the enabling powers outlined in Part 2 of the Medicines and Medical Devices Act 2021 (MMDA) to amend the Medicines Act 1968 and the
HMRs.
Furthermore, the DHSC has decided to proceed with the implementation of the two models of hub and spoke dispensing that it consulted on.
The government response to the consultation reads: "Having considered the responses, the government intend to proceed to implement the necessary changes to medicines
legislation to remove the current restrictions that prevent the hub and spoke dispensing models from operating across different legal entities found in section 10 of
the Medicines Act 1968.
The Royal Pharmaceutical Society (RPS) is refreshing its Professional Standards for Homecare Services and will be shared for consultation in August to allow
comment and input on the updated content.
The final version is expected to be completed in the autumn.
The standards were originally published in 2013 and are a framework to support teams providing and commissioning homecare services. Homecare medicines services
deliver medication, and any necessary associated care, direct to the patient's home with their consent.
The standards help patients experience a consistent quality of homecare services, irrespective of provider, will protect them from avoidable incidents and help them
get the best outcomes from their medicines.
Jennifer Allen, The Chief Pharmaceutical Officer's Clinical Fellow leading the refresh at RPS said: "It has been 10 years since the first set of Homecare Standards
were published, so it is important that they are reviewed and brought up to date to reflect current service design, medicine pathways and delivery models to ensure
patients receive safe and effective medication supply and associated care."
HRA Pharma's progestogen-only contraceptive pill, Hana, has won the 'Special Achievement Award' at the Nicolas Hall awards.
The awards took place on May 5, 2022 in Athens. HRA's Marketing Director for the UK, Ireland and the Nordics, Kate Evans, was in attendance to represent the Hana
team and accept the award.
The Hana pill became available in July 2021 for women in the UK to purchase without a prescription following a pharmacy consultation.
The launch has made it easier for women to access effective daily contraception. This reclassification made HRA Pharma one of the leaders in this new healthcare category. The switch followed the authorisation of reclassification of desogestrel by UK regulator MHRA. Hana was one of the first products to enter this new market.
Britain's health regulator is poised to announce that hormone replacement therapy (HRT) will be made available over the counter for the first time, the Daily Telegraph has revealed.
The newspaper first reported on Tuesday (February 1) that watchdogs were set to propose a reclassification of the medication so women are able to access it in a pharmacy without a prescription.
Every year, some 1.5 million women experience difficult menopausal symptoms, such as hot flushes, night sweats, sleep disturbance and a variety of emotional problems.
But only a tenth of them are prescribed HRT, following a consultation with a GP or specialist.
According to the newspaper, the latest proposal aims to improve convenience so that women are able to access HRT more easily, without needing a GP appointment.
In its first, the National Institute for Health and Care Excellence (NICE) has recommended the use of Pre Exposure Prophylaxis (PrEP) to treat people at the
highest risk of catching HIV.
The announcement comes along with a consultation on draft guideline by NICE on reducing sexually transmitted infections.
NICE's recommendation is backed up by the government's HIV Action Plan to hit zero new transmissions of HIV by 2030.
The pill prevents HIV by stopping the virus from crossing into the healthy cells and replicating.
According to the UK PROUD study, PrEP reduced the risk of HIV infection by 86 per cent for men who have sex with men.
However, people taking the pill must also get regular HIV testing and STI screening done every three months.
The government has previously committed to introducing several new family-friendly rights following numerous consultations over the last few years.
These include: neonatal leave and pay; carer's leave; and extending redundancy protection for pregnant women and new parents.
The government confirmed it would implement these reforms in the long-awaited Employment Bill, first announced in the Queen's speech back in 2019.
However, the Employment Bill was not referred to in the Queen's speeches in both May 2021 and May 2022 therefore it remains unclear when these reforms will be
prioritised.
Nevertheless, at this stage, it is helpful for pharmacy business owners and managers to have an understanding of the direction of travel when it comes to family
friendly rights in the workplace.
The NHS has launched plans to expand pioneering subscription-style drug contracts to develop lifesaving antibiotics of the future.
It is building on its world-first pilot to incentivise the pharmaceutical industry to develop new antibiotics that could be offered to NHS patients when they
need them the most.
The consultation has launched almost a year to the day that contracts for two superbug-busting drugs were rolled out as part of a world-first pilot.
Cefiderocol and ceftazidime-avibactam, new antibiotics manufactured by Shionogi and Pfizer respectively, were awarded world-first subscription contracts which
provided the companies with a fixed annual fee based primarily on the availability of the drugs and their value to the NHS, as opposed to the volumes used.
By breaking the link between the payments companies receive and the number of their antibiotics prescribed, the NHS is removing any incentive to overuse antibiotics,
decreasing the risk of life-threatening infections, such as sepsis and pneumonia, becoming resistant to treatment.
Reena Mehta, consultant pharmacist in the Critical Care team at NHS King's College Hospital, has been announced as chair of the Learning Division for the
Intensive Care Society.
Mehta took up the post with effect from 8th April, and is the first pharmacist to hold the role of Chair of the Learning Division within the Society.
"It is a privilege to be part of the Society and support its life-saving work to enhance our understanding of critical illness and deliver better care to patients,"
"The intensive care community is made up of multiple professions, each playing a vital role within the critical care team, and I am extremely proud to be the first
pharmacist appointed to this important role."
In her role as chair of the Learning Division, Mehta will oversee the content of the Society's study days and be responsible for exploring new opportunities for the
Intensive Care Society to provide training for our multi professional intensive care community.
HRA Pharma is celebrating the 1st anniversary of Hana, the first type of daily oral contraception available in the UK without a prescription.
The launch of Hana in 2021 followed the historic decision of the Medicines and Healthcare products Regulatory Agency (MHRA) to grant a marketing authorisation
and marked a significant step forward in the women's contraception category.
The company reports that pharmacists have embraced the reclassification and have found merit in using emergency contraception consultations as an opportunity to
educate women on their over-the-counter contraception options.
Alison Slingsby, innovations project manager at HRA Pharma, commented: "We have been delighted with Hana's reception - within weeks of launch, it quickly became
the best-selling mini-pill without prescription, with more than 95 per cent market share, and has maintained this market leading position ever since. We previously
had the experience of switching emergency contraceptive ellaOne to a P medicine, Hana is on track to match and eventually exceed the ellaOne volumes.
Scotland has become the world's first country to introduce a simple blood test for Type 1 diabetes patients, enabling them to stop taking insulin by improving the accuracy of diagnosis.
The routine C-peptide test, introduced today (November 1), will allow doctors to know how much insulin someone with diabetes is making themselves.
The roll-out of test follows a two-year pilot study in NHS Lothian led by diabetes and endocrinology consultant Professor Mark Strachan.
Strachan said: "C-peptide helps diabetes specialists make a more accurate diagnosis of the cause of diabetes, and that means we can get people on the most appropriate treatment. In some instances, C-peptide testing allowed people to stop very long-standing insulin therapy; this can be life-transforming."
In response to new research that revealed inequality in menopause support with 51 per cent of women from black, Asian and minority ethnic backgrounds,
Holland & Barrett, the UK's leading health and wellness retailer, has decided to continue its menopause campaign work to make "every menopause matter".
A quarter of women (26 per cent) from minority ethnic communities say they find it difficult to access menopause support relevant to their specific backgrounds.
Alongside support from Olympian and menopause campaigner, Michelle Griffith Robinson and expert, Meera Bhogal, the retailer is launching several new initiatives
to make its information and support on menopause more inclusive by offering more diverse and personalised advice and content, tailored to different needs.
Almost a third (31 per cent) believe being able to speak to a female healthcare professional of the same ethnicity as them would have made a difference to their
menopause experience. Fifteen per cent go as far as saying that communicating in their native language would have made a positive difference.
Based on these findings, Holland and Barrett is the first retailer to launch a free, multi-language menopause online consultation service. The service will
see trained H&B menopause advisors offering guidance and symptom support in multiple languages, starting with Hindi, Urdu, Gujarati and Punjabi.